Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women Living With HIV (C-3001B-P-CS7)
Comparison of Clinic-based Versus Clinic-plus Community Outreach-based Strategy Via HPV Self-Collection to Increase Uptake of Cervical Cancer Screening Among Women Living With HIV: a Cluster Randomized Trial (CASCADE-3001-B)
This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE)-3001-B trial aims to assess how the introduction of a community-health-worker-facilitated model, in addition to the existing static clinic-only model, influences the rates of cervical cancer screening uptake among women living with HIV (WLWH). This study involves offering human papillomavirus (HPV) self-collection for cervical cancer screening to eligible WLWH.
The 'CASCADE' Network is a clinical trials network aimed at improving cervical cancer screening, management, and pre-cancer treatment for WLWH, in various healthcare settings. The network will conduct implementation trials to improve the triage of HPV-positive WLWH, as well as algorithms to optimize access to and options for effective treatment. Trials will be conducted using a mixed-methods approach aimed at assessing implementation strategies and outcomes and their potential to integrate into existing health systems.
Further understanding of HPV-based community-based strategies to reach WLWH, and the acceptability, feasibility, appropriateness, and cost of these strategies will be valuable for cervical cancer screening programs serving WLWH. Inputs from various 'CASCADE' Clinical Sites (CS) regarding feasible screening outreach options available in their settings for WLWH have guided this study that focuses on evaluating a pragmatic HPV self-collection implementation model to improve access to screening.
While it is clear that HPV self-collection is a highly acceptable and feasible screening option, creating opportunities to conduct self-collection in alternative venues outside the clinic premises, and with the guidance of and facilitation by trusted community healthcare workers (CHWs) is an important implementation strategy that needs to be evaluated and considered for its potential benefit. Studies have not yet evaluated a community-based approach for HPV self-collection kit distribution among WLWH - who may have different characteristics, preferences, and access to screening services than women not living with HIV. Providing WLWH with the option of receiving HPV self-collection kits in their own homes or other community-based settings ('community-based HPV self-collection') is a novel implementation strategy that could improve cervical cancer screening rates among eligible women. Therefore, this novel trial aims to evaluate the feasibility and effectiveness of implementing community-based HPV self-collection among WLWH.
調査の概要
状態
詳細な説明
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jennifer Smith, PhD
- 電話番号:919-445-6911
- メール:jennifers@unc.edu
研究連絡先のバックアップ
- 名前:Poonam Rawat, MPH
- 電話番号:919-445-6911
- メール:Poonam.Rawat@unc.edu
研究場所
-
-
-
Harare、ジンバブエ、263-772287143
- University of Zimbabwe Clinical Trials Research Centre
-
コンタクト:
- Bothwell T Guzha, MD
- 電話番号:263-772287143
- メール:bothwellguzha@gmail.com
-
主任研究者:
- Bothwell T Guzha, MD
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Clinic Inclusion Criteria
- Clinics selected for inclusion will include those clinics that provide Human Immunodeficiency Virus (HIV) care and distribute antiretroviral therapy (ART) to Women living with Human Immunodeficiency Virus (WLWH.
- These clinics should also have the ability to collect their own data.
- Such clinics could be supported by national programs and bilateral donor-funded initiatives
Inclusion Criteria for Medical Record Abstraction
- Are living with Human Immunodeficiency Virus (HIV)
- Are 25-49 years of age, or as recommended by the Zimbabwe National Screening Guidelines
- Live in the catchment areas of or attend a study-eligible clinic
- Are eligible for Human Papillomavirus (HPV)-based cervicovaginal testing either because:
- They have never undergone cervical cancer screening before, or
- They have never undergone HPV-based testing before and are now due for Visual Inspection with Acetic Acid and Cervicography (VIAC), per national guidelines, or
- They have previously undergone HPV-based testing, and are now due for follow-up HPV-based testing per national guidelines, and /or
- They underwent ablative or excisional treatment for presumed or confirmed cervical dysplasia >1 year ago and have not had any follow-up cervical cancer screening since treatment.
Exclusion Criteria for Medical Record Abstraction
- Have had their cervix removed
- Are pregnant or <6 weeks post-delivery
- Were positive on their most recent cervical cancer screening test and referred for further evaluation or treatment, but did not complete their referral
- Have previously been treated for invasive cervical cancer
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ふるい分け
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:モデル1クリニックで登録された参加者
モデル1クリニックに登録されたヒト免疫不全ウイルス感染女性(WLWH)。
|
Model 1 involves only the recommended standard-of-care of cervical cancer screening Human Papillomavirus (HPV) self-collection, if available, or Visual Inspection with Acetic Acid and Cervicography (VIAC), if HPV-based testing is not available) to clients who are due for screening at clinics that distribute Antiretroviral Therapy (ART) to Women living with Human Immunodeficiency Virus (WLWH).
Efforts will be made to ensure availability of HPV kits for Model 1 clinics.
|
|
実験的:Participants enrolled at Model 2 Clinics
Women living with Human Immunodeficiency Virus (WLWH) enrolled at Model 2 Clinics.
|
Model 2 will include clinic-based Human Papillomavirus (HPV) self-collection, as well as the implementation strategy of providing community-based distribution for HPV self-collection via Community Health workers (CHWs).
Women living with Human Immunodeficiency Virus (WLWH) who are due and overdue for cervical cancer screening will be identified via line lists and appointment directories.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cervical cancer monthly screening rates
時間枠:Up to 1 month
|
Monthly cervical cancer screening rates among Women living with Human Immunodeficiency Virus (WLWH) will be compared between two models: (1) standard-of-care screening at static clinics only (Model 1) , and (2) Human Papillomavirus (HPV) self-collection offered at static clinics and through a community-based strategy by community health workers (CHWs)(Model 2). Standard-of-care for Model 1 is defined as HPV self-collection when available or Visual Inspection with Acetic Acid and Cervicography (VIAC) when HPV-based screening is not available. |
Up to 1 month
|
協力者と研究者
捜査官
- スタディディレクター:Michael Hudgens, PhD、University of North Carolina, Chapel Hill
- スタディチェア:Jennifer Tang, MD、UNC Lineberger Comprehensive Cancer Center
- 主任研究者:Jennifer Smith, PhD、UNC Lineberger Comprehensive Cancer Center
- スタディディレクター:Katie Mollan, PhD、University of North Carolina, Chapel Hill
- スタディディレクター:Lameck Chinula, MD、University of North Carolina, Chapel Hill
- スタディディレクター:Lisa Spees, PhD、University of North Carolina, Chapel Hill
- スタディディレクター:Chemtai Mungo, MD MPH、University of North Carolina, Chapel Hill
- スタディディレクター:Vikrant Sahasrabuddhe, MBBS, MPH, DrPH、Division of Cancer Prevention (DCP)
- スタディディレクター:Sue Siminski, MS, MBA、Frontier Science Foundation
- スタディディレクター:Zvavahera M Chirenje, MD、University of California, San Francisco
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 25-0894
- U24CA275417 (米国 NIH グラント/契約)
- UG1CA275403 (米国 NIH グラント/契約)
- UG1CA284918 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。